Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0) has announced strategic appointments to its Board of Directors and corporate governance team, effective immediately. The clinical-stage oncology company, which is developing therapies for hard-to-treat cancers, appointed Zachary T. Stadnyk, a former TSX Life Sciences Lead and biotech capital markets executive, to its Board. Natalia L. Butterworth, Director of Corporate Secretarial and Governance at ARO Consulting Inc., has been appointed Corporate Secretary.
Mr. Stadnyk brings over 15 years of experience in biotechnology, capital markets, and public company leadership. He previously served as Head of Life Sciences at the TSX and TSXV, advising biotech issuers, boards, and institutional investors on public listings, capital formation, and strategic positioning. Over his career, he has led and supported over $100 million in institutional financings and contributed to strategic transactions, including the $435 million acquisition of The Supreme Cannabis Company by Canopy Growth. He has also advised public companies across biotech, healthcare, and AI sectors.
Ms. Butterworth is a seasoned corporate governance professional with over 15 years of experience supporting public and private companies in governance and regulatory compliance across multiple jurisdictions, including the pharmaceutical, technology, and finance sectors. Based in British Columbia, both appointees strengthen Helix's Canadian capital markets and governance expertise as the company advances its capital markets strategy, including preparations for a planned Nasdaq listing through the Multijurisdictional Disclosure System (MJDS).
Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix BioPharma, commented on the appointments: "As Helix continues to execute on its corporate and clinical development objectives, strengthening our capital markets and governance capabilities remains a key priority. Zach brings a wealth of experience across biotechnology financing, public markets and strategic transactions, while Natalia adds strong governance and corporate secretarial expertise. These appointments come at an important time for Helix as we finalize the clinical protocol for L-DOS47 and actively prepare for a Nasdaq listing under the MJDS, including ongoing audit, governance, and capital markets readiness initiatives."
Zachary Stadnyk, Director of Helix BioPharma, added: "I am excited to join Helix at such a pivotal stage in its development. The Company's differentiated approach to addressing the tumor microenvironment and its clear path toward a Nasdaq listing creates a compelling opportunity. I look forward to supporting the team in advancing its capital markets strategy and unlocking value for its shareholders."
In connection with its ongoing capital markets and governance initiatives, Helix also announced that it is in the process of relocating its registered and records office from Toronto, Ontario to Vancouver, British Columbia. This move aligns with the strengthening of the company's governance and capital markets infrastructure as it advances its Nasdaq uplisting strategy under the MJDS framework.
Helix BioPharma is an oncology company focused on developing near-term solutions for hard-to-treat cancers. Its pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC). The company also advances LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug. Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). For more information, visit https://www.helixbiopharma.com/.
The appointments and relocation efforts signal Helix's commitment to enhancing its governance and capital markets expertise as it moves toward a Nasdaq listing. This strategic positioning could provide the company with greater access to U.S. capital markets, potentially accelerating the development of its oncology pipeline and offering shareholders increased liquidity and visibility.
